PUBLIC CONTRACT · 2023

4180139/2023 - Durvalumab 500 mg (50 mg/ml AMP 10 ml) sol inj

Contract value: €79,516.80
Signed on: 8 March 2023
Procedure: Ao abrigo de acordo-quadro (art.º 258.º)

This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.

Record 9892377

PUBLISHED SUBJECT

4180139/2023 - DURVALUMAB 500 MG (50 MG/ML AMP 10 ML) SOL INJ

Parties involved

Contracting body: CHBM - Centro Hospital Barreiro Montijo, EPE
Awardee: ASTRAZENECA - PROD.FARMACEUTICOS, LDA.
Place of performance: Portugal, Setúbal, Barreiro
NUTS region: Not stated

WHO BID

Awardee and competitors

Companies that IMPIC lists as the awardee and as competitors in this procedure.

Awardee: ASTRAZENECA - PROD.FARMACEUTICOS, LDA. · Tax ID 502942240

Values and timeline

Contract price: €79,516.80
Procedure base price: €0.00
Total effective price: €79,516.80
Publication date: 28 March 2023
Award date: 8 March 2023
Signing date: 8 March 2023
Performance period: 275 days

The contract price is the value agreed in the contract, not the amount paid.

Procedure and framework

Contract type: Aquisição de bens móveis
Procedure type: Ao abrigo de acordo-quadro (art.º 258.º)
Award criterion: Monofator
CPV code: 33600000-6 - Produtos farmacêuticos
Legal basis: Artigo 258.º do Código dos Contratos Públicos
Regime: Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
Framework agreement: CP 2021/6 - Medicamentos do foro oncológico e imunomoduladores
Centralised procedure: No
Environmental criterion: No
Notice: Not stated
Procedure identifier: 6374055

Compare with other contracts

Search the same body, supplier, place or type of service to understand the context of the published index.

← Back to contracts